[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data

Tango Therapeutics (NASDAQ: TNGX) is scheduled to report first-quarter 2026 earnings on Monday, May 11, before the market opens, with a conference call set for Friday, May 15 at 9:00 AM ET. The central question for investors: can this precision oncology biotech sustain momentum after a volatile 2025 that saw both a massive Q3 earnings beat and subsequent losses? With analysts forecasting a loss of ($0.32) per share and the stock trading 94% above its 200-day moving average, the stakes are high for a company navigating the transition from clinical development to potential commercialization.

Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines that...

Fundamentals

See More
  • Market Capitalization, $K 3,386,802
  • Shares Outstanding, K 144,242
  • Annual Sales, $ 62,380 K
  • Annual Income, $ -101,590 K
  • EBIT $ -110 M
  • EBITDA $ -111 M
  • 60-Month Beta 1.22
  • Price/Sales 54.61
  • Price/Cash Flow N/A
  • Price/Book 9.19

Options Overview Details

View History
  • Implied Volatility 153.00% (+12.79%)
  • Historical Volatility 80.67%
  • IV Percentile 24%
  • IV Rank 16.15%
  • IV High 777.13% on 05/12/25
  • IV Low 32.80% on 09/04/25
  • Expected Move (DTE 7) 3.95 (17.17%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 312
  • Volume Avg (30-Day) 993
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 22,330
  • Open Int (30-Day) 8,166
  • Expected Range 19.07 to 26.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.32
  • Number of Estimates 6
  • High Estimate $-0.28
  • Low Estimate $-0.38
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.68 +16.94%
on 04/10/26
28.41 -18.97%
on 04/21/26
+2.96 (+14.76%)
since 04/08/26
3-Month
10.80 +113.15%
on 03/02/26
28.41 -18.97%
on 04/21/26
+10.51 (+84.01%)
since 02/06/26
52-Week
1.07 +2,051.40%
on 05/12/25
28.41 -18.97%
on 04/21/26
+21.92 (+1,992.73%)
since 05/08/25

Most Recent Stories

More News
Tango Therapeutics Pivotal Trial Launch Timing Matters More Than the Vopimetostat Monotherapy Data

Barchart Research What to Expect from TNGX Earnings TNGX Generated May 8, 2026 Current Price $23.02 EPS Estimate $$-0.32 Consensus Rating Strong Buy Average Move 12.99% Tango Therapeutics Pivotal Trial...

TNGX : 23.02 (-1.96%)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted...

TNGX : 23.02 (-1.96%)
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

-  Matthew Gall appointed Chief Financial Officer  - -  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026...

TNGX : 23.02 (-1.96%)
This Stock Is Up 1,229% in Just the Past Year, But Don’t Bet Your Retirement Money on It

Tango Therapeutics (TNGX) has surged 1,229% over the past year. Shares are trading at a new all-time high and have strong technical momentum. TNGX maintains a 100% “Buy” technical opinion from Barchart....

TNGX : 23.02 (-1.96%)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors...

TNGX : 23.02 (-1.96%)
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical...

TNGX : 23.02 (-1.96%)
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S....

TNGX : 23.02 (-1.96%)
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to...

TNGX : 23.02 (-1.96%)
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Founding CEO Barbara Weber, M.D. to become executive chair of the board of directors Malte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately...

TNGX : 23.02 (-1.96%)
Tango Therapeutics Appoints Sung Lee to Board of Directors

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 23.02 (-1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 24.64
2nd Resistance Point 24.27
1st Resistance Point 23.65
Last Price 23.02
1st Support Level 22.66
2nd Support Level 22.29
3rd Support Level 21.67

See More

52-Week High 28.41
Last Price 23.02
Fibonacci 61.8% 17.97
Fibonacci 50% 14.74
Fibonacci 38.2% 11.51
52-Week Low 1.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.